Abstract Sarcoidosis is a chronic inflammatory disease with a complex pathogenesis and unknown etiology characterized by noncaseating granulomas that invade the lungs, eyes, liver and other organs. Insertion (I)/deletion (D) polymorphism in the gene encoding the angiotensin-converting enzyme (ACE) has been studied to examine the genetic predisposition to sarcoidosis in different populations, but the results have been inconsistent and inconclusive. This study aimed to determine the frequencies of the genotypes and alleles of I/D polymorphism in the ACE gene in Turkish patients as a distinct ethnic group and to investigate whether such polymorphism is associated with predisposition to sarcoidosis. Genomic DNA samples obtained from 154 individuals (70 patients with sarcoidosis and 84 healthy controls) were used in the study. The DNA was amplified using polymerase chain reactions using allele-specific primers. The amplified products were analyzed by 2 % agarose gel electrophoresis followed by UV transillumination. The allele frequencies and genotype distribution of the groups were analyzed using the Chi square test. There were no significant differences between the controls and sarcoidosis cases with respect to genotype distribution (v 2 = 4.202, p = 0.122) and allele frequencies (v 2 = 1.358, p = 0.244). Our results suggest that I/D polymorphism in the ACE gene does not cause a genetic predisposition to sarcoidosis in Turkish patients.
Introduction
Sarcoidosis is a multi-system disease characterized by noncaseating epithelioid granulomas with unknown etiology. It has a worldwide distribution with regional variations in frequency because of differences in environmental exposure, genetic factors and surveillance methods (Bell 1991) . A 2-year study, completed in 2007, was performed by the Clinical Issues Study Group of the Turkish Thoracic Society, finding that the annual incidence of sarcoidosis in Turkey was 4 in 100,000 (Musellim et al. 2009 ). Sarcoidal granulomas may occur in any organ, and in more than 90 % of the patients, they occur in the lungs, intrathoracic lymph nodes, eyes, and skin. Although the inciting event is unknown, the pathophysiology of the disorder is as an antigen-driven process. The granulomatous lesions occur because of immune responses in the genetically susceptible individuals exposed to environmental antigens (Iannuzzi et al. 2007 ). Sarcoidosis-specific noncaseating granulomas release distinct cytokines and mediators. Of these molecules, the angiotensin-converting enzyme (ACE) is most commonly known and is believed to play an important role in the pathogenesis of the disease (Ainslie and Benatar 1985) . Approximately 40 years ago, Lieberman was the first to report that the serum ACE activity increases in patients with sarcoidosis (Lieberman 1975) . Because epithelioid cells of sarcoid granulomas produce ACE, and serum ACE levels are elevated in sarcoidosis patients, the serum ACE level is proposed to be the marker of sarcoidosis activity and susceptibility (Ainslie and Benatar 1985; Yotsumoto 1982 ; Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993 1994 .
The ACE is a zinc metalloprotease primarily synthesized in epithelial cells surrounding the proximal tubules of the kidneys and the luminal face of the lungs (Ehlers and Riordan 1989) . ACE converts angiotensin I into angiotensin II, which is a potential vasoconstrictor through its dipeptide carboxypeptidase activity and inactivates bradykinin, substance P and neurokinin A (Maliarik et al. 1998) . The ACE gene is located in the 17q23 chromosomal region in humans (Hubert et al. 1991) . Twenty-eight types of polymorphism have been detected in the ACE gene (Rieder et al. 1999) . Of these, the best-studied type is the ACE insertion/deletion (I/D) polymorphism. I/D polymorphism was defined based on the presence or absence, respectively, of a 287 bp ALU sequence in intron 16 of the ACE gene. As a result of this polymorphism, insertion/insertion (II), insertion/deletion (ID), and deletion/deletion (D) genotypes are generated (Maliarik et al. 1998 ). In healthy individuals, the DD, ID, and II genotypes are correlated with the highest, intermediate, and lowest serum enzyme levels, respectively (Rigat et al. 1990) .
I/D polymorphism in the ACE gene affects the ACE enzyme level in metabolic diseases like hypertension and sarcoidosis (Gunes et al. 2004; Furuya et al. 1996; Tomita et al. 1997; Biller et al. 2009 ). Therefore, the ACE genotype might be a genetic marker (Furuya et al. 1996; Tomita et al. 1997; Biller et al. 2009; Papadopoulos et al. 2000; Sharma and Alam 1995; Salobir et al. 2007; Tahir et al. 2007) . Along with the detection of familial sarcoidosis, research on genetic predisposition to sarcoidosis has gained momentum (Fite et al. 1998; Rybicki et al. 1996; Sverrild et al. 2008) . However, contradictory results were obtained using different ethnic groups; therefore, further studies are required to test whether the ACE genotype is linked to sarcoidosis predisposition (Maliarik et al. 1998; McGrath et al. 2001; Alia et al. 2005; Kruit et al. 2010; Schurmann et al. 2001; Hatemi et al. 2001) . The objectives of our study were to determine the distribution of I/D polymorphism in the ACE gene in Turkish patients as a distinct ethnic group and to investigate whether such polymorphism is associated with a predisposition to sarcoidosis.
Materials and methods

Study population
This study included 70 patients who reported to the Department of Chest Diseases of the Medical Faculty at the Eskisehir Osmangazi University and were diagnosed with sarcoidosis and followed up regularly; these patients did not have any familial connections. The diagnosis of sarcoidosis was made using clinical and radiologic findings, by histologically confirming non-necrotic granulomatous inflammation and excluding other causes. In all cases, standard clinical evaluation was performed including anamnesis, physical examination, chest radiography, ECG, biochemical blood tests for the diagnosis and follow-up of sarcoidosis, diffusion capacity for carbon monoxide (DLCO) and pulmonary function tests (PFT). Forced expiratory volume at the first second (FEV1), forced vital capacity (FVC), FEV1/FVC, DLCO, and specific diffusion (DLCO/Va) were recorded as the percentage of expected values according to the age, gender, and height of the patient. Eighty-four unrelated healthy individuals were included in the study as a control group. The demographic characteristics of the study groups and PFT findings are shown in Table 1 . Approval was obtained from the Ethics Committee of the Medical Faculty of the Eskisehir Osmangazi University dated 13.08.2010 and numbered 2010/7. Each individual who participated in the study voluntarily signed an informed consent form.
Genotyping
Venous blood samples from the studied individuals were collected in EDTA tubes. The DNA of each individual was isolated from the blood samples using the salt method as previously described (Gunes et al. 2004) . As described in the same study, amplification of the DNA samples was performed using the sense oligonucleotide primer 5 0 CTG CAG ACC ACT CCC ATC CTT TCT 3 0 and the antisense oligonucleotide primer 5 0 GAT GTG GCC ATC ACA TTC GTC AGA T 3 0 designed to detect ACE I/D polymorphism (Gunes et al. 2004) . One hundred nanograms of genomic DNA samples was amplified by 30 cycles of denaturation at 92°C for 40 s, annealing at 56°C for 40 s and extension at 72°C for 40 s, using a 50 ll of PCR mixture containing 10 pmol of each primer, 19 PCR buffer (Vivantis Technologies, Selangor, Malaysia) with magnesium chloride, 2.5 mM dNTPs, and 1.25 U of thermostable Taq polymerase (Vivantis Technologies). The PCR products were electrophoresed on 2 % agarose gels containing 4 ml of ethidium bromide in TRIS-borate ethylenediaminetetraacetic acid buffer. The PCR products were visualized using a transilluminator equipped with a CCD camera. The results were evaluated using the Gel Analysis software (LabWorks, Cambridge, UK). The reactions generate 190 and 490 bp products in the absence and presence of the insertion in the ACE gene, respectively, as previously described (Fig. 1) (Papadopoulos et al. 2000) .
Statistical analysis
The differences between the observed levels were analyzed using ''SPSS for Windows version 13'' (Chicago, IL, USA) statistics software. The continuous variables were represented as the means ± standard deviations (SD). The allele and genotype frequencies in patients with sarcoidosis and healthy individuals were compared using the Chi square test (v 2 -test). P values below 0.05 were considered to represent significant differences. 
Results
As previously reported, 490 and 190 bp PCR products are obtained using the insertion and deletion alleles, respectively (Papadopoulos et al. 2000) . Three genotypes are possible: II, ID, and DD. The distributions of ACE genotypes and alleles in Turkish patients and healthy individuals are shown in Table 2 . In the studied patients with sarcoidosis, the II, ID, and DD genotype frequencies were 21.4, 48.6, and 30 %, respectively. The frequencies of the I and D alleles in these patients were 54.3 and 45.7 %, respectively. In the control group, the II, ID, and DD genotype frequencies were 21.4, 61.9, and 16.7 %, respectively. The frequencies of the I and D alleles in the healthy individuals were 47.6 and 52.4 %, respectively. There was no significant difference between the genotype frequencies in sarcoidosis patients and healthy individuals (v 2 = 4.202, p = 0.122). There was also no significant difference in the allele frequencies in the two groups (v 2 = 1.358, p = 0.244). Furthermore, the ID genotype frequency was higher in the healthy individuals compared to the sarcoidosis patients; however, the difference was not significant.
Discussion
Since the discovery by Lieberman over 40 years ago that the ACE enzyme levels were higher in sarcoidosis patients compared to healthy individuals, the ACE gene has gained importance in sarcoidosis research (Lieberman 1975) . Initial studies focused on comparison of the ACE enzyme levels, whereas later studies have focused on the genetic factors affecting the enzyme levels (Ainslie and Benatar 1985) . It was proposed that I/D polymorphism in the ACE gene affected the ACE enzyme level (Rigat et al. 1990 ). However, the ACE D allele and DD genotype were proposed to increase ACE levels in healthy individuals and patients with sarcoidosis (Furuya et al. 1996) .
We studied Turkish patients with sarcoidosis and did not observe an association between the risk of sarcoidosis and I/D polymorphism in the ACE gene. There was no significant difference between the patient and control groups with respect to either genotype or allele frequencies. The ID genotype frequency was higher in healthy individuals compared to sarcoidosis patients, but the difference was not significant.
Several studies have examined the relationship between sarcoidosis and I/D polymorphism in the ACE gene; these studies were conducted on different ethnic groups, and the results were not consistent. Maliarik et al. studied African Americans and Caucasians, did not observe a significant difference in the ACE genotype between 60 Caucasians diagnosed with sarcoidosis and 48 healthy individuals, but they detected a significant difference in the genotypic distribution in 183 African Americans diagnosed with sarcoidosis compared to 111 individuals from the control group. Whereas the risk of sarcoidosis in African Americans was 1.30 times higher in individuals with the ID genotype, the risk increased by 3.17 times in individuals with the DD genotype. In the same ethnic group, disease risk was found to significantly increase with the DD genotype in patients with positive family history (Maliarik et al. 1998) . In a study on British and Czechoslovakian patients diagnosed with sarcoidosis, McGrath et al. examined the correlation between the ACE genotype and disease sensitivity, severity, and progression, but they did not observe significant association (McGrath et al. 2001) . Consistent with the results of our study, Hatemi et al. (Furuya et al. 1996) . In a study by Papadopoulos et al. sarcoidosis patients were divided into groups based on the presence of autoimmune manifestations. The DD genotype was more prevalent in patients with autoimmune manifestations and in X-ray stage III (Papadopoulos et al. 2000) . Tahir et al. compared the ACE genotypes of 72 Indian sarcoidosis patients and 199 healthy Indian individuals, and they observed allele ratios of I/D:0.6/0.4 in the control group and I/D:0.35/0.65 in sarcoidosis patients. Whereas the risk of developing sarcoidosis was 9 times higher in patients with the D allele (DD ? ID), patients with the II genotype had 5.5 times higher disease risk (Tahir et al. 2007 ). Schurmann et al. studied German families and reported that the DD genotype was present at a high level in patients with sarcoidosis (Schurmann et al. 2001) . Similarly, Salobir et al. observed that the D allele frequency was higher in a Slovenian patient group compared to the control group, and they suggested that I/D polymorphism in the ACE gene might be associated with predisposition to sarcoidosis (Salobir et al. 2007) .
Therefore, the association between I/D polymorphism in the ACE gene and sarcoidosis differs among ethnic groups. The ACE genotype affected the enzyme level in the same manner in all studies. However, further studies on larger numbers of patients are needed to examine genotype-associated predisposition to sarcoidosis. Spagnolo and Schwartz noted that several new questions have been raised by the discovery of other candidate genes for the genetic predisposition to sarcoidosis (Spagnolo and Schwartz 2013) . Therefore, GWAS (genome-wide association studies) are required in all ethnic groups.
Further studies are required to understand the contributions of the ACE gene and other genetic factors in Turkish sarcoidosis patients; we hope that our study contributes to this goal. We did not observe a significant correlation between I/D polymorphism in the ACE gene and the risk of sarcoidosis; therefore, comprehensive studies on Turkish patients are required and may produce different results. In addition, the trend towards increased ID genotype frequency in healthy individuals (although not significantly increased) suggests that this genotype might protect against sarcoidosis.
